vs

Side-by-side financial comparison of Eventbrite, Inc. (EB) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Eventbrite, Inc. is the larger business by last-quarter revenue ($73.5M vs $37.2M, roughly 2.0× Organogenesis Holdings Inc.). On growth, Eventbrite, Inc. posted the faster year-over-year revenue change (-3.9% vs -57.1%). Over the past eight quarters, Eventbrite, Inc.'s revenue compounded faster (-7.7% CAGR vs -46.5%).

Eventbrite is an American live events marketplace and website. The service allows users to browse, create, and promote local events. It is free to publish unlimited events of any size on Eventbrite.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

EB vs ORGO — Head-to-Head

Bigger by revenue
EB
EB
2.0× larger
EB
$73.5M
$37.2M
ORGO
Growing faster (revenue YoY)
EB
EB
+53.2% gap
EB
-3.9%
-57.1%
ORGO
Faster 2-yr revenue CAGR
EB
EB
Annualised
EB
-7.7%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
EB
EB
ORGO
ORGO
Revenue
$73.5M
$37.2M
Net Profit
$-8.2M
Gross Margin
68.1%
30.8%
Operating Margin
-12.4%
-185.1%
Net Margin
-11.1%
Revenue YoY
-3.9%
-57.1%
Net Profit YoY
2.5%
EPS (diluted)
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EB
EB
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$73.5M
$225.6M
Q3 25
$71.7M
$150.9M
Q2 25
$72.8M
$101.0M
Q1 25
$73.8M
$86.7M
Q4 24
$76.5M
$126.7M
Q3 24
$77.8M
$115.2M
Q2 24
$84.6M
$130.2M
Net Profit
EB
EB
ORGO
ORGO
Q1 26
Q4 25
$-8.2M
$43.7M
Q3 25
$6.4M
$21.6M
Q2 25
$-2.1M
$-9.4M
Q1 25
$-6.6M
$-18.8M
Q4 24
$-8.4M
$7.7M
Q3 24
$-3.8M
$12.3M
Q2 24
$1.1M
$-17.0M
Gross Margin
EB
EB
ORGO
ORGO
Q1 26
30.8%
Q4 25
68.1%
Q3 25
67.9%
Q2 25
67.5%
Q1 25
66.9%
72.6%
Q4 24
68.2%
75.5%
Q3 24
68.5%
76.7%
Q2 24
70.9%
77.6%
Operating Margin
EB
EB
ORGO
ORGO
Q1 26
-185.1%
Q4 25
-12.4%
28.1%
Q3 25
-1.3%
13.7%
Q2 25
-8.7%
-12.5%
Q1 25
-13.2%
-30.9%
Q4 24
-10.2%
8.1%
Q3 24
-11.5%
5.4%
Q2 24
-7.6%
-10.7%
Net Margin
EB
EB
ORGO
ORGO
Q1 26
Q4 25
-11.1%
19.4%
Q3 25
8.9%
14.3%
Q2 25
-2.9%
-9.3%
Q1 25
-9.0%
-21.7%
Q4 24
-11.0%
6.1%
Q3 24
-4.8%
10.7%
Q2 24
1.3%
-13.1%
EPS (diluted)
EB
EB
ORGO
ORGO
Q1 26
Q4 25
$-0.08
$0.31
Q3 25
$0.06
$0.11
Q2 25
$-0.02
$-0.10
Q1 25
$-0.07
$-0.17
Q4 24
$-0.09
$0.05
Q3 24
$-0.04
$0.09
Q2 24
$0.01
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EB
EB
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$299.9M
$91.4M
Total DebtLower is stronger
$144.4M
Stockholders' EquityBook value
$179.1M
Total Assets
$647.2M
$520.0M
Debt / EquityLower = less leverage
0.81×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EB
EB
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$299.9M
$93.7M
Q3 25
$63.7M
Q2 25
$73.1M
Q1 25
$110.0M
Q4 24
$441.5M
$135.6M
Q3 24
$24.7M
$94.3M
Q2 24
$56.7M
$89.9M
Total Debt
EB
EB
ORGO
ORGO
Q1 26
Q4 25
$144.4M
Q3 25
$174.9M
Q2 25
$241.3M
Q1 25
$241.0M
Q4 24
$240.7M
Q3 24
$240.4M
$62.3M
Q2 24
$358.7M
$63.8M
Stockholders' Equity
EB
EB
ORGO
ORGO
Q1 26
Q4 25
$179.1M
$300.1M
Q3 25
$189.1M
$255.1M
Q2 25
$177.2M
$233.2M
Q1 25
$173.3M
$242.9M
Q4 24
$170.2M
$262.9M
Q3 24
$179.8M
$278.5M
Q2 24
$176.2M
$263.5M
Total Assets
EB
EB
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$647.2M
$598.7M
Q3 25
$744.6M
$509.8M
Q2 25
$784.1M
$461.1M
Q1 25
$812.3M
$467.4M
Q4 24
$752.3M
$497.9M
Q3 24
$817.4M
$446.3M
Q2 24
$894.5M
$443.2M
Debt / Equity
EB
EB
ORGO
ORGO
Q1 26
Q4 25
0.81×
Q3 25
0.92×
Q2 25
1.36×
Q1 25
1.39×
Q4 24
1.41×
Q3 24
1.34×
0.22×
Q2 24
2.04×
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EB
EB
ORGO
ORGO
Operating Cash FlowLast quarter
$-60.8M
Free Cash FlowOCF − Capex
$-60.9M
FCF MarginFCF / Revenue
-82.8%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$17.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EB
EB
ORGO
ORGO
Q1 26
Q4 25
$-60.8M
$39.4M
Q3 25
$36.7M
$3.1M
Q2 25
$-17.5M
$-32.9M
Q1 25
$59.4M
$-19.9M
Q4 24
$-45.3M
$10.9M
Q3 24
$44.6M
$8.7M
Q2 24
$-32.3M
$4.7M
Free Cash Flow
EB
EB
ORGO
ORGO
Q1 26
Q4 25
$-60.9M
$34.8M
Q3 25
$36.6M
$844.0K
Q2 25
$-17.5M
$-36.5M
Q1 25
$59.4M
$-23.6M
Q4 24
$-45.3M
$7.6M
Q3 24
$44.4M
$6.1M
Q2 24
$-32.4M
$2.9M
FCF Margin
EB
EB
ORGO
ORGO
Q1 26
Q4 25
-82.8%
15.4%
Q3 25
51.1%
0.6%
Q2 25
-24.1%
-36.1%
Q1 25
80.4%
-27.2%
Q4 24
-59.2%
6.0%
Q3 24
57.1%
5.3%
Q2 24
-38.3%
2.2%
Capex Intensity
EB
EB
ORGO
ORGO
Q1 26
Q4 25
0.0%
2.1%
Q3 25
0.0%
1.5%
Q2 25
0.0%
3.6%
Q1 25
0.1%
4.2%
Q4 24
0.0%
2.7%
Q3 24
0.2%
2.2%
Q2 24
0.1%
1.4%
Cash Conversion
EB
EB
ORGO
ORGO
Q1 26
Q4 25
0.90×
Q3 25
5.76×
0.14×
Q2 25
Q1 25
Q4 24
1.43×
Q3 24
0.71×
Q2 24
-30.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EB
EB

US$52.0M71%
Other$21.6M29%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons